The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
September 27th 2011, 10:03am
The European Multidisciplinary Cancer Congress
Pictures from The 2011 European Multidisciplinary Cancer Congress (EMCC) in Stockholm, Sweden
September 26th 2011, 10:26am
The European Multidisciplinary Cancer Congress
Radiotherapy can be given between or during chemotherapy cycles, rather than sequentially, for women with early breast cancer.
September 26th 2011, 8:41am
The European Multidisciplinary Cancer Congress
Aflibercept added to FOLFIRI chemotherapy improved PFS and OS in previously treated patients with metastatic colorectal cancer.
September 25th 2011, 5:42am
The European Multidisciplinary Cancer Congress
T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.
September 25th 2011, 5:05am
The European Multidisciplinary Cancer Congress
Panitumumab + chemo improves OS and PFS in patients with metastatic carcinoma of the head and neck that were negative for HPV.
September 24th 2011, 4:27pm
The European Multidisciplinary Cancer Congress
Investigational drug that emits alpha radiation shows significant improvement in overall survival.
September 24th 2011, 3:35pm
The European Multidisciplinary Cancer Congress
Patients with liver metastases from uveal melanoma had improved survival after treatment with percutaneous hepatic perfusion (PHP).
September 23rd 2011, 9:43am
The European Multidisciplinary Cancer Congress
Two studies enhance understanding of risk factors for prostate cancer.
September 23rd 2011, 7:24am
The European Multidisciplinary Cancer Congress
The 16th ECCO, 36th ESMO, 30th ESTRO Congresses from the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23-27.
June 8th 2011, 4:43pm
American Society of Clinical Oncology (ASCO) 2011 Annual Meeting Daily Picture Slideshow
June 7th 2011, 12:06pm
Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial.
June 7th 2011, 11:34am
Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada discusses mortalities in cabozantinib trial.
June 7th 2011, 9:42am
Women who present with BRCA1 and BRCA2 mutation face an increased risk of breast and ovarian cancer.
June 7th 2011, 9:22am
Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing
June 7th 2011, 8:08am
Phosphatase and tensin homolog (PTEN)-positive breast cancer can be treated with trastuzumab (Herceptin) as effectively as PTEN-negative breast cancer
June 7th 2011, 7:31am
American Society of Clinical Oncology 2011 Annual Meeting Picture Slideshow Day Four
June 7th 2011, 6:04am
Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib
June 6th 2011, 10:09am
Luminal A genetic signature in node-negative, estrogen receptor- (ER-) positive breast cancer predicts a very high disease-free survival rate
June 6th 2011, 9:47am
Lapatinib and capecitabine is a reasonable approach in a well-informed patient with brain metastasis and HER2+ breast cancer
June 6th 2011, 7:07am
New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted